Poseida Therapeutics (PSTX) said Thursday that it has nominated a new development candidate as part of its collaboration with Roche, resulting in a $15 million milestone payment from the Swiss healthcare company.
Poseida said the candidate is an allogeneic, dual CAR-T therapy that targets known antigens found in hematologic malignancies, including multiple myeloma.
The company said it and Roche had completed three programs under a collaboration agreement signed in August 2022.
Shares of Poseida Therapeutics were up more than 1% in recent trading.
Price: 2.57, Change: +0.03, Percent Change: +1.18
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。